181 related articles for article (PubMed ID: 32540170)
21. Spotlight on ranolazine in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
[TBL] [Abstract][Full Text] [Related]
22. Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study.
Arnold SV; Spertus JA; Lipska KJ; Tang F; Goyal A; McGuire DK; Cresci S; Maddox TM; Kosiborod M
Eur J Prev Cardiol; 2015 Jun; 22(6):779-87. PubMed ID: 24740679
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman BR
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
[TBL] [Abstract][Full Text] [Related]
24. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
[TBL] [Abstract][Full Text] [Related]
26. Predictors of long-term clinical endpoints in patients with refractory angina.
Povsic TJ; Broderick S; Anstrom KJ; Shaw LK; Ohman EM; Eisenstein EL; Smith PK; Alexander JH
J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637344
[TBL] [Abstract][Full Text] [Related]
27. New Anti-Anginal Drugs: Ranolazine.
Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
29. Treatment of stable angina pectoris.
Palaniswamy C; Aronow WS
Am J Ther; 2011 Sep; 18(5):e138-52. PubMed ID: 20861717
[TBL] [Abstract][Full Text] [Related]
30. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
31. Evolving treatment strategies for chronic refractory angina.
Yang EH; Barsness GW
Expert Opin Pharmacother; 2006 Feb; 7(3):259-66. PubMed ID: 16448320
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological approaches of refractory angina.
Giannopoulos AA; Giannoglou GD; Chatzizisis YS
Pharmacol Ther; 2016 Jul; 163():118-31. PubMed ID: 27013345
[TBL] [Abstract][Full Text] [Related]
33. Ranolazine for Refractory Angina in a Heart Transplant Recipient With Cardiac Allograft Vasculopathy.
Yeung DF; Toma M; Davis MK; Ignaszewski A
Am J Transplant; 2017 May; 17(5):1427-1428. PubMed ID: 28035732
[No Abstract] [Full Text] [Related]
34. Concomitant Use of Ranolazine and Trimetazidine in Patients with Refractory Angina: An Initial Experience.
Dourado LOC; Moreno CPD; Grobe SF; Gowdak LHW; Cesar LAM
Arq Bras Cardiol; 2022 Oct; 119(4):619-621. PubMed ID: 35946755
[No Abstract] [Full Text] [Related]
35. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
[TBL] [Abstract][Full Text] [Related]
36. Long-term benefits and limitations of combined antianginal drug therapy in elderly patients with symptomatic chronic coronary artery disease.
Bonetti PO; Kaiser C; Zellweger MJ; Grize L; Erne P; Schoenenberger RA; Pfisterer ME;
J Cardiovasc Pharmacol Ther; 2005 Mar; 10(1):29-37. PubMed ID: 15821836
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
38. Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study.
Olympios C; Stafylas P; Dermitzakis A; Efthimiadis I; Gardikiotis A; Kakouros S; Lampropoulos S; Barbetseas J; Sourgounis A; On Behalf Of Ranger Investigators
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541898
[No Abstract] [Full Text] [Related]
39. Feasibility of Extracorporeal Shock Wave Myocardial Revascularization Therapy for Post-Acute Myocardial Infarction Patients and Refractory Angina Pectoris Patients.
Myojo M; Ando J; Uehara M; Daimon M; Watanabe M; Komuro I
Int Heart J; 2017 Apr; 58(2):185-190. PubMed ID: 28320996
[TBL] [Abstract][Full Text] [Related]
40. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Yuriivna Osovska N; Vitaliivna Kuzminova N
Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
